Share Twitter LinkedIn Facebook Email Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports.
SGNTUC-024 Phase 1b/2 study: Tucatinib, trastuzumab, FOLFOX for HER2+ GI cancers Gastrointestinal 8 Mins Read